Schizophrenia Clinical Trial
Official title:
Life Goals Behavioral Change to Improve Outcomes for Veterans With SMI
Persons with serious mental illness are at increased risk of cardiovascular disease. The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and to get feedback from patients and providers on what is needed to help better coordinate and physical and mental health care of these patients.
Background: Persons with serious mental illness (SMI, including schizophrenia, bipolar
disorder, or chronic affective disorders) experience a disproportionate burden of medical
comorbidity, notably cardiovascular disease (CVD), leading to poor functioning and premature
mortality. CVD risk factors in persons with SMI are attributable to unhealthy lifestyles
exacerbated by mental health-related symptoms, medication side effects (e.g., weight gain),
and the fragmentation of physical and mental health services.
Objectives: The specific aims of this rapid response proposal pilot study are 1) to adopt
and test the feasibility of an evidence-based psychosocial intervention (Life Goals
Collaborative Care- or LGCC) designed to promote health behavioral change that was developed
for bipolar disorder to a broader SMI patient population, and 2) to describe the
implementation of LGCC and the barriers and facilitators of adoption to a more generalizable
SMI patient population, and to vet the program to key VA stakeholders in order to inform a
larger implementation study across different VHA settings.
Methods: LGCC is a novel manual-based intervention that incorporates behavioral change
strategies within a Chronic Care Model-based program. It is designed to reduce risk factors
for cardiovascular disease (CVD), through improved control of psychiatric symptoms and
increased positive health behaviors, as well as improved coordination of physical and mental
health care. We will enroll 100 individuals diagnosed with a chronic mental disorder and CVD
risk factor who are also receiving care within the VA Ann Arbor Healthcare System mental
health clinics, of which 50 will be randomized to LGCC, and 50 randomized to receive usual
care. LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral
change within the context of patients' psychiatric symptoms; 2) participant goal setting in
diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient
contacts with a health specialist for 6 months, in addition to 4) strategies to increase
provider access and support for behavioral change and medical management. Outcomes will be
assessed to determine whether effect sizes are comparable to previously published LGCC
randomized controlled trials, and include mental and physical health-related quality of life
and long-term (10-year) CVD risk based on the Framingham risk score assessed at 6 months.
Additional mixed methods analyses of administrator, consumer and provider interviews to
inform further adoption of LGCC will also be completed.
Impact: Serious mental illness is associated with significant disability, decreased quality
of life, and a decreased life span. VA patients with SMI die an average of 13-18 years
earlier than age and gender matched individuals from the U.S. population, mostly from CVD.
Interventions such as LGCC that combine individualized lifestyle coaching with Chronic Care
Model principles may lead to the greatest impact on this public health crisis because they
address multiple reasons for health disparities, and behavior change is reinforced through
improved coordination and continuity of care. If effective, LGCC could be easily
disseminated in VA practices and aligned with emerging VHA "T-21" initiatives around
veteran-centered care (patient-centered medical home) and behavioral medicine programs that
can ultimately improve outcomes for veterans with mental disorders.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |